Shan Xu
About
In The Last Decade
Shan Xu
79 papers receiving 866 citations
Peers
Comparison fields: 5 of 118
- Molecular Biology 287
- Oncology 137
- Biomaterials 100
- Cancer Research 96
- Electrical and Electronic Engineering 89
Countries citing papers authored by Shan Xu
This map shows the geographic impact of Shan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shan Xu more than expected).
Fields of papers citing papers by Shan Xu
This network shows the impact of papers produced by Shan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shan Xu. The network helps show where Shan Xu may publish in the future.
Co-authorship network of co-authors of Shan Xu
This figure shows the co-authorship network connecting the top 25 collaborators of Shan Xu. A scholar is included among the top collaborators of Shan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shan Xu. Shan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 0 | |
| 3 | 12 | |
| 4 | 2 | |
| 5 | 17 | |
| 6 | 0 | |
| 7 | 6 | |
| 8 | 5 | |
| 9 | 7 | |
| 10 | Serum IL-8 and VEGFA are Two Promising Diagnostic Biomarkers of Asthma-COPD Overlap Syndrome | 1 |
| 11 | Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive EGFR/ALK Mutation-Negative Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma with High Tumor Mutation Burden: A Case Report | 1 |
| 12 | A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells | 1 |
| 13 | Predictors of Insulin Treatment During Pregnancy and Abnormal Postpartum Glucose Metabolism in Patients with Gestational Diabetes Mellitus | 2 |
| 14 | Identification of prognostic risk factors for esophageal adenocarcinoma using bioinformatics analysis | 2 |
| 15 | Nerve growth factor delivery by ultrasound-mediated nanobubble destruction as a treatment for acute spinal cord injury in rats | 2 |
| 16 | Protective effect of fucoidan from Fucus vesiculosus on liver fibrosis via the TGF-β1/Smad pathway-mediated inhibition of extracellular matrix and autophagy | 21 |
| 17 | 0 | |
| 18 | 44 | |
| 19 | A case of hypertrophic olivary degeneration after resection of cavernomas of the brain stem and review of the literature | 2 |
| 20 | Spectrum-effect relationship in antipyretic effect of Huangqin(Radix Scutellariae) | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.